This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nguyen, D. M. Articles by Chang, J. C. Search for Related Content PubMed PubMed Citation Articles by Nguyen, D. M. Articles by Chang, J. C.

Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype

Authors' Affiliation: Breast Center, Baylor College of Medicine, Houston, Texas

Requests for reprints: Jenny C. Chang, Breast Center, Baylor College of Medicine and The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030. Phone: 713-798-1905; Fax: 713-798-8884; E-mail: jcchang{at}breastcenter.tmc.edu.

Purpose: Inflammatory breast cancer (IBC) is associated with very poor prognosis. The aims of this study are (a) to prospectively identify differential gene expression patterns associated with IBC and (b) to confirm these pathways using tissue arrays.

Experimental Design: For gene expression analysis, IBC (n = 14) was clinically defined as rapid-onset cancer associated with erythema and skin changes, whereas non-IBC patients (n = 20) had stage III breast cancers, and cDNA analysis was carried out using the Affymetrix (Santa Clara, CA) HG-U133A microarrays. Tissue arrays were constructed from paraffin-embedded material, and the molecular phenotype of 75 IBC was compared with results from >2,000 non-IBC.

Results: Gene expression analyses indicated that IBC has higher expression of genes associated with increased metabolic rate, lipid signaling, and cell turnover relative to non-IBC tumors. Consistent with the expression analysis, IBC had statistically higher Ki-67 (93% versus 11%; P < 0.001). BAX expression, reflecting increased apoptosis and cell turnover, was significantly uniformly higher in almost all IBC (98% versus 66%; P < 0.05), whereas the expression of Bcl-2 was not significantly different. IBC tumors were more likely to be steroid hormone receptor negative (estrogen receptor, 49% versus 30%; P = 0.002; progesterone receptor, 68% versus 42%; P = 0.001). The expression of tyrosine kinases was not significantly different. E-cadherin was found to be expressed in 87% of IBC, whereas the expression p53 was not significantly different.

Conclusion: This study is one of the largest molecular analyses of IBC. Both IBC and non-IBC are genetically heterogeneous with consistent differences in the molecular phenotype of IBC.

This article has been cited by other articles:

				R. S. Mehta, T. Schubbert, and K. Kong Trastuzumab in inflammatory breast cancer Ann. Onc., October 1, 2008; 19(10): 1815 - 1817. [Full Text] [PDF]

				S. Johnston, M. Trudeau, B. Kaufman, H. Boussen, K. Blackwell, P. LoRusso, D. P. Lombardi, S. Ben Ahmed, D. L. Citrin, M. L. DeSilvio, et al. Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy J. Clin. Oncol., March 1, 2008; 26(7): 1066 - 1072. [Abstract] [Full Text] [PDF]

				K. M. Aird, X. Ding, A. Baras, J. Wei, M. A. Morse, T. Clay, H. K. Lyerly, and G. R. Devi Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression Mol. Cancer Ther., January 1, 2008; 7(1): 38 - 47. [Abstract] [Full Text] [PDF]

				Y. Nieto, F. Nawaz, R. B. Jones, E. J. Shpall, and S. Nawaz Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast Cancer J. Clin. Oncol., October 1, 2007; 25(28): 4405 - 4413. [Abstract] [Full Text] [PDF]